Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2012 3
2013 4
2014 2
2015 3
2016 5
2017 5
2018 3
2019 2
2020 18
2021 17
2022 18
2023 21
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. Hepatology. 2023. PMID: 37363821 Free PMC article.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
NAFLD and cardiovascular diseases: a clinical review.
Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. Kasper P, et al. Among authors: demir m. Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7. Epub 2020 Jul 21. Clin Res Cardiol. 2021. PMID: 32696080 Free PMC article. Review.
Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
Knorr J, Kaufmann B, Inzaugarat ME, Holtmann TM, Geisler L, Hundertmark J, Kohlhepp MS, Boosheri LM, Chilin-Fuentes DR, Birmingham A, Fisch KM, Schilling JD, Loosen SH, Trautwein C, Roderburg C, Demir M, Tacke F, Hoffman HM, Feldstein AE, Wree A. Knorr J, et al. Among authors: demir m. Hepatology. 2023 Jun 1;77(6):1968-1982. doi: 10.1002/hep.32776. Epub 2022 Oct 12. Hepatology. 2023. PMID: 36059147 Free PMC article.
Complement activation induces excessive T cell cytotoxicity in severe COVID-19.
Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Georg P, et al. Among authors: demir m. Cell. 2022 Feb 3;185(3):493-512.e25. doi: 10.1016/j.cell.2021.12.040. Epub 2021 Dec 28. Cell. 2022. PMID: 35032429 Free PMC article.
The fecal mycobiome in non-alcoholic fatty liver disease.
Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, Bang C, Roderburg C, Tacke F, Steffen HM, Goeser T, Kruglov A, Eckmann L, Stärkel P, Fouts DE, Schnabl B. Demir M, et al. J Hepatol. 2022 Apr;76(4):788-799. doi: 10.1016/j.jhep.2021.11.029. Epub 2021 Dec 10. J Hepatol. 2022. PMID: 34896404 Free PMC article.
Management of alcoholic hepatitis: A clinical perspective.
Kasper P, Lang S, Steffen HM, Demir M. Kasper P, et al. Among authors: demir m. Liver Int. 2023 Oct;43(10):2078-2095. doi: 10.1111/liv.15701. Epub 2023 Aug 22. Liver Int. 2023. PMID: 37605624 Review.
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt HH, Schramm C, Willuweit K, Lange CM, Weber S, Denk G, Berg CP, Grottenthaler JM, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle PR, Sprinzl M, Lohse AW, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter FP, Schlevogt B, Gödiker J, Hofmann WP, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K. Dietz-Fricke C, et al. Among authors: demir m. JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 37025462 Free PMC article.
89 results